FBInvestor
Stocks / Recursion Pharmaceuticals In
Institutional Ownership

Recursion Pharmaceuticals In

CUSIP 75629V104CL ARXRXQ1 2026

13D / 13G Filings
34
Schedule 13D/13G on record
Beneficial Filers
15
Distinct reporting persons
Largest Stake
13.9%
Max % of class reported
Institutional Holders
327
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

34 filings · latest Feb 5, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 5, 2026Baillie Gifford &Amp; Co13G/A4.6%23.77MSEC
2Feb 3, 2026Ark Investment Management LLC13G/A7.3%37.32MSEC
3Dec 23, 2025Mubadala Investment Co Pjsc13D/A1.4%SEC
4Apr 4, 2025Yohan Kim13G5.9%267.5KSEC
5Feb 14, 2025Ra Capital Management, L.P.13G/A2.0%7.73MSEC
6Feb 14, 2025Ark Investment Management LLC13G/A8.5%32.35MSEC
7Feb 5, 2025Blackrock, Inc.13G/A6.1%23.44MSEC
8Nov 12, 2024Vanguard Group Inc13G/A8.8%24.27MSEC
9Nov 12, 2024Fmr LLC13G/A3.0%SEC
10Nov 8, 2024Blackrock, Inc.13G/A7.5%20.74MSEC

24 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Recursion Pharmaceuticals In.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →